FrancophonIA/ELRC3.0 huggingface dataset:
English: The results of these fed studies demonstrate that Lansoprazole's bioavailability is not only markedly reduced when taken with food, but that its absorption, in the presence of food, can be very erratic.
Slovenian: Rezultati teh študij pri bolnikih, ki so zdravilo jemali na poln želodec, kažejo, da biološka razpoložljivost zdravila Lansoprazola, kadar se ga jemlje skupaj s hrano, ni samo znatno manjša, temveč da je v prisotnosti hrane lahko zelo neurejena.
English: Lansoprazole is a proton pump inhibitor that inhibits gastric acid secretion and is used for the treatment of duodenal and benign gastric ulcers, gastrooesophageal reflux disease and associated conditions.
Slovenian: Lansoprazol je zaviralec protonske črpalke, ki zavira izločanje želodčne kisline in se uporablja za zdravljenje razjed v dvanajstniku in benignih razjed v želodcu, za zdravljenje gastroezofagealne refluksne bolezni in s tem povezanih bolezenskih stanj.
English: The valid Summary of Product Characteristics, labelling and package leaflet are the final versions achieved during the Coordination group procedure as mentioned in Annex III.
Slovenian: Veljavni Povzetek glavnih značilnosti zdravila, označevanje in Navodilo za uporabo zdravila so končne različice, ki so bile pripravljene med postopkom Skupine za usklajevanje, kot je omenjeno v Dodatku III.
English: It was considered that this wider criterion can be applied in this case because of the extremely high intra-subject variability (70- 82%) under fed conditions shown in this study.
Slovenian: Prisotno je bilo mnenje, da se zaradi izredno velike variabilnosti znotraj posameznih bolnikov (70 do 82 %), ki se je v tej študiji pokazala v razmerah, ko so bolniki zdravilo jemali na poln želodec, v tem primeru lahko uporabi to širše merilo.
English: Lansoprazole 15 & 30 mg gastro-resistant capsules, hard (Teva UK Ltd) are generic preparations containing lansoprazole as the active substance.
Slovenian: Lansoprazol 15 mg in 30 mg gastrorezistentne trde kapsule (Teva UK Ltd) sta generični zdravili, ki vsebujeta zdravilno učinkovino lansoprazol.
English: Box 217, 3640 AE Mijdrecht The Netherlands
Slovenian: Industrieweg 23, P.O. Box 217, 3640 AE Mijdrecht The Netherlands
English: The objecting Concerned Member States raised public health objections on the grounds that while bioequivalence was proven in the fasting state, the same was not the case under fed conditions.
Slovenian: Zadevne države članice, ki so nasprotovale, so z utemeljitvijo, da je bila biološka enakovrednost dokazana pri bolnikih, ki so zdravilo jemali na tešče, ni pa bila dokazana pri bolnikih, ki so zdravilo jemali na poln želodec, opozorile na zadržke, povezane z javnim zdravjem.
English: Although the CI for the fed study results (CI for AUCinf.
Slovenian: Čeprav so se vrednosti intervala zaupanja (CI) pri rezultatih študije, v kateri so bolniki zdravilo jemali na poln želodec (CI za AUCinf.
English: Box 217, 3640 AE Mijdrecht, The Netherlands,
Slovenian: Teva Pharma B.V., Industrieweg 23, P.O. Box 217, 3640 AE Mijdrecht, The Netherlands,
English: Teva Pharma B.V., Industrieweg 23, P.O.
Slovenian: Teva Pharma B.V., Industrieweg 23, P.O. Box 217, 3640 AE Mijdrecht,
English: Lansoprazole TEVA 15 mg Gastro-resistant Capsules
Slovenian: Lansoprazol TEVA 15 mg Cápsula gastro-resistente
English: Lansoprazole TEVA 30 mg Gastro-resistant Capsules
Slovenian: Lansoprazol TEVA 30 mg Cápsula gastro-resistente
English: Date of first authorisation: 16 November 2004 Date of latest renewal: 18 July 2014
Slovenian: Datum prve odobritve: 16. november 2004 Datum zadnjega podaljšanja: 18. julij 2014
English: They are marked with ‘S 063'.
Slovenian: Označene so z ‘S 063'.
English: The holder of this marketing authorisation must inform the European Commission about the marketing plans for the medicinal product authorised by this decision.
Slovenian: Imetnik tega dovoljenja za promet z zdravilom mora obvestiti Evropsko komisijo o načrtu trženja za zdravilo, odobreno s to odločbo.
English: The bottle also contains a small sealed container.
Slovenian: Steklenica vsebuje tudi majhen zatesnjen vsebnik.
English: • If you have or think you might have a problem with your heart;
Slovenian: • če imate ali mislite, da imate težavo s srcem;
English: Therefore platelets should be monitored frequently.
Slovenian: Zato je treba krvne ploščice pogosto spremljati.
English: 9/l or a ≥ 50% reduction from baseline and maintenance of the reduction for at least 4 weeks.
Slovenian: 9/l ali ≥ 50 % zmanjšanje od prvotne vrednosti in ohranitev zmanjšanja vsaj štiri tedne.
English: The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list)) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.
Slovenian: Zahteve glede predložitve rednega posodobljenega poročila o varnosti zdravila za to zdravilo so določene v seznamu referenčnih datumov EU (seznamu EURD), opredeljenem v členu 107c(7) Direktive 2001/83/ES, in vseh kasnejših posodobitvah, objavljenih na evropskem spletnem portalu o zdravilih.
English: Tell your doctor if you are pregnant or are planning to become pregnant.
Slovenian: Povejte zdravniku, če ste noseči ali načrtujete nosečnost.
English: Within the system organ classes they are listed under the following headings: Very common (≥ 1/10); Common (≥ 1/100 to < 1/10); Uncommon (≥ 1/1,000 to < 1/100); Rare (≥ 1/10,000 to < 1/1,000); Very rare (< 1/10,000), not known (cannot be estimated from the available data).
Slovenian: Navedeni so po organskih sistemih z naslednjimi opisi pogostnosti: zelo pogosti (≥ 1/10); pogosti (≥ 1/100 do < 1/10); občasni (≥ 1/1000 do < 1/100); redki (≥ 1/10000 do < 1/1000); zelo redki (< 1/10000), neznana (ni mogoče oceniti iz razpoložljivih podatkov).
English: However, as expected, patients in this age group had twice the incidence of serious adverse events (mainly cardiac).
Slovenian: Kot je bilo pričakovano, so bolniki v tej starostni skupini dvakrat pogosteje doživljali hude težave (v glavnem s srcem).
English: If you are worried, speak to your doctor.
Slovenian: Če vas skrbi, se pogovorite s svojim zdravnikom.
English: • The effects of food on bioavailability are not considered clinically relevant to the use of anagrelide.
Slovenian: • Učinki hrane na biološko uporabnost niso klinično relevantni za uporabo anagrelida.
English: After this time, your doctor may either increase or decrease the number of capsules that you take to find the dose best suited to you and which treats your condition most effectively.
Slovenian: Po tem obdobju vam utegne zdravnik povečati ali zmanjšati število kapsul, da odkrije odmerek, ki vam najbolj ustreza in ki je najbolj učinkovit za vašo bolezen.
English: Xagrid or these medicines may not work properly if taken together.
Slovenian: Zdravilo Xagrid ali ta zdravila morda ne bodo imela pravega učinka, če jih boste jemali skupaj.
English: Food also decreased the Cmax of the active metabolite, 3-hydroxyanagrelide, by 29%, although it had no effect on the AUC.
Slovenian: Hrana je tudi zmanjšala Cmax aktivnega presnovka, 3-hidroksi-anagrelida, za 29 %, čeprav ni imela vpliva na AUC.
English: An opaque white hard capsule imprinted with S 063.
Slovenian: Bela neprozorna trda kapsula z natisnjeno oznako S 063.
English: The dose increment must not exceed more than 0.5 mg/day in any one-week and the recommended maximum single dose should not exceed 2.5 mg (see section 4.9).
Slovenian: Povišanje odmerka ne sme presegati več kot 0,5 mg dnevno v katerem koli tednu, priporočen najvišji enkratni odmerek pa ne sme preseči 2,5 mg (glejte poglavje 4.9).
English: It is not recommended in patients with elevated transaminases (> 5 times the upper limit of normal) (see sections 4.2 and 4.3).
Slovenian: Ni priporočljivo pri bolnikih s povišanimi ravnmi transaminaz (> 5-krat večje od zgornje meje normale) (glejte poglavji 4.2 in 4.3).
English: Discontinuation of treatment should be considered in paediatric patients who do not have a satisfactory treatment response after approximately 3 months.
Slovenian: Prekinitev zdravljenja pride v poštev pri pediatričnih bolnikih, ki se po približno 3 mesecih ne odzovejo zadovoljivo na zdravljenje.
English: Adverse reactions arising from clinical studies, post-authorisation safety studies and spontaneous reports are presented in the table below.
Slovenian: Neželeni učinki zdravila, opisani v kliničnih študijah, študijah varnosti po odobritvi zdravila in spontanih poročilih, so predstavljeni v spodnji preglednici.
English: Linearity Dose proportionality has been found in the dose range 0.5 mg to 2 mg.
Slovenian: Linearnost Proporcionalnost odmerku so ugotovili v razponu odmerkov od 0,5 mg do 2 mg.
English: There are limited pharmacokinetic data for this patient population.
Slovenian: Za to skupino bolnikov so na voljo omejeni farmakokinetični podatki.
English: In a two-year rat carcinogenicity study, non-neoplastic and neoplastic findings were observed and related or attributed to an exaggerated pharmacological effect.
Slovenian: V dvoletni raziskavi karcinogenosti pri podganah, so opazovali ne-neoplastične in neoplastične ugotovitve ter jih povezali ali pripisovali prekomernemu farmakološkemu učinku.
English: Pharmacokinetic data from healthy subjects established that food decreases the Cmax of anagrelide by 14%, but increases the AUC by 20%.
Slovenian: Farmakokinetični podatki, pridobljeni od zdravih oseb, dokazujejo, da hrana zmanjša Cmax anagrelida za 14 %, a zveča AUC za 20 %.
English: The disease may progress to myelofibrosis or AML.
Slovenian: Bolezen lahko napreduje v mielofibrozo ali AML.
English: If you have been told that you have an intolerance to some sugars, contact your doctor before taking this medicine.
Slovenian: Če vam je zdravnik povedal, da imate intoleranco za nekatere sladkorje, se pred uporabo tega zdravila posvetujte z zdravnikom.
English: Mutagenic and carcinogenic potential Studies on the genotoxic potential of anagrelide did not identify any mutagenic or clastogenic effects.
Slovenian: Mutageni in karcinogeni potencial Pri raziskavah genotoksičnega potenciala anagrelida niso odkrili mutagenih ali klastogenih učinkov.
English: After one week the dose may be titrated, on an individual basis, to achieve the lowest effective dose required to reduce and/or maintain a platelet count below 600 x 10
Slovenian: Po enem tednu lahko titrirate odmerek pri vsakem bolniku posamezno, da dosežete najnižji učinkovit odmerek, potreben za zmanjševanje in/ali ohranjanje števila krvnih ploščic pod 600 x 10
English: What Xagrid is and what it is used for
Slovenian: Kaj je zdravilo Xagrid in za kaj ga uporabljamo
English: 9/l or
Slovenian: 9/l in
English: If you take more Xagrid than you should or if someone else has taken your medicine, tell a doctor or pharmacist immediately.
Slovenian: Če ste vzeli večji odmerek zdravila Xagrid, kot bi smeli, ali če je zdravilo vzel kdo drug, o tem takoj obvestite zdravnika ali farmacevta.
English: Women who are at risk of becoming pregnant should make sure that they are using effective contraception when taking Xagrid.
Slovenian: Ženske, pri katerih obstaja tveganje, da zanosijo, morajo poskrbeti za uporabo učinkovite kontracepcije, ko jemljejo zdravilo Xagrid.
English: Limited pharmacokinetic and/or pharmacodynamic studies investigating possible interactions between anagrelide and other medicinal products have been conducted.
Slovenian: Opravili so omejene farmakokinetične in/ali farmakodinamične raziskave, v katerih so preiskovali možna medsebojna delovanja anagrelida in drugih zdravil.
English: Your doctor will ask you to have blood tests at regular intervals to check that your medicine is working effectively and that your liver and kidneys are working well.
Slovenian: Zdravnik vas bo v enakomernih intervalih napotil na krvne preiskave, da bo preveril, ali zdravilo učinkuje in ali vaša jetra in ledvice delujejo dobro.
English: Pharmacotherapeutic group: Other antineoplastic agents, ATC Code: L01XX35.
Slovenian: Farmakoterapevtska skupina: Druga zdravila z delovanjem na novotvorbe (citostatiki), oznaka ATC: L01XX35.
English: In the absence of specific paediatric guidelines, WHO diagnostic criteria for adult diagnosis of ET are considered to be of relevance to the paediatric population.
Slovenian: Ob pomanjkanju posebnih pediatričnih smernic velja, da so za pediatrično populacijo pomembna diagnostična merila SZO za diagnozo ET pri odraslih.
English: Less than 1% is recovered in the urine as anagrelide.
Slovenian: Manj kot 1 % ga prestrežemo v urinu v obliki anagrelida.
English: Typically, a fall in the platelet count will be observed within 14 to 21 days of starting treatment and in most patients an adequate therapeutic response will be observed and maintained at a dose of 1 to 3 mg/day (for further information on the clinical effects refer to section 5.1).
Slovenian: Običajno opazimo padec števila krvnih ploščic v 14 do 21 dneh od začetka zdravljenja in pri večini bolnikov bo ustrezen terapevtski odgovor opazen in vzdrževan pri odmerku od 1 do 3 mg dnevno (za dodatne informacije o kliničnih učinkih glejte poglavje 5.1).
English: There is limited information on the use of Xagrid in children and adolescents and therefore this medicine should be used with caution.
Slovenian: O uporabi zdravila Xagrid pri otrocih in mladostnikih je podatkov malo, zato je treba to zdravilo uporabljati previdno.
English: 9/l and ideally at levels between 150 x 10 9/l and 400 x 10 9/l.
Slovenian: 9/l in v idealnih razmerah na stopnji med 150 x 10
English: 48 patients aged 6-17 years (19 children and 29 adolescents) have received anagrelide for up to 6.5 years either in clinical studies or as part of a disease registry (see section 5.1).
Slovenian: Oseminštirideset bolnikov, starih 6-17 let (19 otrok in 29 mladostnikov), je prejemalo anagrelid do 6,5 let dolgo bodisi v kliničnih študijah bodisi v okviru registra bolezni (glejte poglavje 5.1).
English: An at risk patient
Slovenian: Bolnik, ki je izpostavljen tveganju
English: • If you are allergic to anagrelide or any of the other ingredients of this medicine (listed in section
Slovenian: • če ste alergični na anagrelid ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
English: Patients with moderate or severe renal impairment (creatinine clearance < 50 ml/min).
Slovenian: Bolniki z zmerno ali močno oslabljenimi ledvicami (očistek kreatinina < 50 ml v minuti).
English: • Fluvoxamine, used to treat depression;
Slovenian: • fluvoksamin za zdravljenje depresij;
English: The amount of Xagrid that people take can be different, and this depends on your condition.
Slovenian: Količina zdravila Xagrid je lahko različna in je odvisna od stopnje vaše bolezni.
English: Do not remove or eat the drying agent.
Slovenian: Ne odstranite in ne pojejte sredstva za sušenje.
English: Hypersensitivity to anagrelide or to any of the excipients listed in section 6.1.
Slovenian: Preobčutljivost na anagrelid ali katero koli pomožno snov, navedeno v poglavju 6.1.
English: Other medicines and Xagrid
Slovenian: Druga zdravila in zdravilo Xagrid
English: Show them the pack of Xagrid.
Slovenian: Pokažite mu embalažo zdravila Xagrid.
English: If you forget to take Xagrid
Slovenian: Če ste pozabili vzeti zdravilo Xagrid
English: The safety and efficacy of anagrelide as a platelet lowering agent have been evaluated in four openlabel, non-controlled clinical trials (study numbers 700-012, 700-014, 700-999 and 13970-301) including more than 4000 patients with myeloproliferative neoplasms (MPNs).
Slovenian: Varnost in učinkovitost anagrelida kot sredstva za zniževanja krvnih ploščic so ovrednotili v štirih odprtih, nekontroliranih študijah, z vsem sodelujočim znanim zdravilom (številke študij 700-012, 700-014, 700-999 in 13970-301), ki so vključevale več kot 4000 bolnikov z mieloproliferativnimi neoplazmami (MPN).
English: The average total daily dose of anagrelide across all studies in paediatric ET patients was highly variable, but overall the data suggest that adolescents could follow similar starting and maintenance doses to adults and that a lower starting dose of 0.5 mg/day would be more appropriate for children over 6 years (see sections 4.2, 4.4, 4.8, 5.2).
Slovenian: Povprečni celotni dnevni odmerek anagrelida v vseh študijah pri pediatričnih bolnikih z ET je močno variiral, v celoti gledano pa podatki kažejo, da bi lahko adolescenti prejemali podobne začetne in vzdrževalne odmerke kot odrasli in da bi bil manjši začetni odmerek, 0,5 mg/dan, za otroke, starejše od 6 let, primernejši (glejte poglavja 4.2, 4.4, 4.8, 5.2).
English: Dose should be decreased or stopped, as appropriate, until the platelet count returns to within the normal range.
Slovenian: Odmerek je treba zmanjšati ali prekiniti dajanje, kot je primernejše, dokler se število krvnih ploščic ne povrne v normalno območje.
English: Name and address of the manufacturer(s) responsible for batch release Shire Pharmaceuticals Ireland Limited, Block 2 & 3 Miesian Plaza, 50 - 58 Baggot Street Lower Dublin 2, Ireland
Slovenian: Ime in naslov izdelovalca (izdelovalcev), odgovornega (odgovornih) za sproščanje serije Shire Pharmaceuticals Ireland Limited, Block 2 & 3 Miesian Plaza, 50 - 58 Baggot Street Lower Dublin 2, Irska
English: It reduces the number of platelets produced by the bone marrow, which results in a decrease in the platelet count in the blood towards a more normal level.
Slovenian: Zmanjšuje število krvnih ploščic, ki jih proizvaja kostni mozeg, posledica tega pa je zmanjšanje števila krvnih ploščic v krvi in približanje normalnejši ravni.
English: During clinical development approximately 50% of the patients treated with anagrelide were over 60 years of age and no age specific alterations in dose were required in these patients.
Slovenian: Med kliničnim razvojem je bilo 50 % bolnikov, zdravljenih z anagrelidom, starejših od 60 let in za te bolnike ni bilo treba posebej spreminjati odmerka zaradi njihove starosti.
English: Treatment with Xagrid should be initiated by a clinician with experience in the management of essential thrombocythaemia.
Slovenian: Zdravljenje z zdravilom Xagrid mora vpeljati klinični zdravnik, ki ima izkušnje z zdravljenjem esencialne trombocitemije.
English: In cell culture studies, anagrelide suppressed expression of transcription factors including GATA-1 and FOG-1 required for megakaryocytopoiesis, ultimately leading to reduced platelet production.
Slovenian: V študijah na celičnih kulturah je anagrelid zaviral ekspresijo transkripcijskih faktorjev, vključno z GATA-1 in FOG-1, ki sta potrebna za megakariocitopoezo, kar je na koncu privedlo do zmanjšanega nastajanja krvnih ploščic.
English: Xagrid is supplied as opaque, white, hard capsules.
Slovenian: Zdravilo Xagrid je na voljo v neprozornih, belih, trdih kapsulah.
English: In patients with essential thrombocythaemia complete response was defined as a decrease in platelet count to ≤ 600 x
Slovenian: Pri bolnikih z esencialno trombocitemijo je bil popoln odziv opredeljen kot zmanjšanje števila krvnih ploščic na ≤ 600 x 10
English: Diagnostic guidelines for essential thrombocythemia should be followed carefully and diagnosis reassessed periodically in cases of uncertainty, with effort made to distinguish from hereditary or secondary thrombocytosis, which may include genetic analysis and bone marrow biopsy.
Slovenian: Skrbno se moramo ravnati po diagnostičnih smernicah za esencialno trombocitemijo in v negotovih primerih redno ponovno ocenjevati diagnozo, pri čemer se moramo truditi, da jo bomo razlikovali od dedne ali sekundarne trombocitoze, kar lahko vključuje genetsko analizo in biopsijo kostnega mozga.
English: If the starting dose is > 1 mg/day platelet counts should be performed every two days during the first week of treatment and at least weekly thereafter until a stable maintenance dose is reached.
Slovenian: Če je začetni odmerek večji od 1 mg dnevno, je treba štetje krvnih ploščic v prvem tednu zdravljenja opravljati vsaka dva dni, potem pa vsaj enkrat tedensko, dokler ne dosežete primernega vzdrževalnega odmerka.
English: The capsules are provided in bottles containing 100 hard capsules.
Slovenian: Kapsule so na voljo v plastenkah, v katerih je po 100 trdih kapsul.
English: Very limited data are available on the use of anagrelide in the paediatric population and anagrelide should be used in this patient group with caution (see sections 4.2, 4.8, 5.1 and 5.2).
Slovenian: O uporabi anagrelida pri otroški populaciji je na voljo zelo malo podatkov, zato ga je pri tej skupini bolnikov treba uporabljati previdno (glejte poglavja 4.2, 4.8, 5.1 in 5.2).
English: What you need to know before you take Xagrid Do not take Xagrid
Slovenian: Kaj morate vedeti, preden boste vzeli zdravilo Xagrid Ne jemljite zdravila Xagrid
English: If treatment is initiated, the benefits and risks of treatment with anagrelide must be monitored regularly and the need for ongoing treatment evaluated periodically.
Slovenian: Če začnemo z zdravljenjem, moramo redno spremljati koristi in tveganja zdravljenja z anagrelidom in v rednih presledkih vrednotiti potrebo po aktualnem zdravljenju.
English: • If you have any problems with your liver or kidneys.
Slovenian: • če imate težave z jetri ali ledvicami.
English: In vitro studies of human megakaryocytopoiesis established that anagrelide's inhibitory actions on platelet formation in man are mediated via retardation of maturation of megakaryocytes, and reducing their size and ploidy.
Slovenian: In vitro študije človeške megakariocitopoeze so pokazale, da se zaviralno delovanje anagrelida na tvorbo krvnih ploščic pri ljudeh odvija prek upočasnitve razvoja megakariocitov ter zmanjšanja njihove velikosti in ploidnosti.
English: The safety of anagrelide has been examined in 4 open label clinical studies.
Slovenian: Varnost anagrelida so proučevali v štirih odprtih kliničnih študijah, z vsem sodelujočim znanim zdravilom.
English: Do not use this medicine after the expiry date which is stated on the carton and bottle label after EXP.
Slovenian: Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in etiketi steklenice poleg oznake EXP. Rok uporabnosti zdravila se izteče na zadnji dan navedenega meseca.
English: If you take more Xagrid than you should
Slovenian: Če ste vzeli večji odmerek zdravila Xagrid, kot bi smeli
English: Repeated dose toxicity
Slovenian: Toksičnost po ponavljajočem se odmerjanju
English: • If you have further questions, ask your doctor or pharmacist.
Slovenian: • Če imate dodatna vprašanja, se posvetujte z zdravnikom ali farmacevtom.
English: The most commonly reported adverse reactions associated with anagrelide were headache occurring at approximately 14%, palpitations occurring at approximately 9%, fluid retention and nausea both occurring at approximately 6% and diarrhoea occurring at 5%.
Slovenian: Najpogosteje zabeleženi neželeni učinki, povezani z anagrelidom, so bili glavobol, ki se je pojavil pri približno 14 % bolnikov, palpitacije so se pojavile pri približno 9 % bolnikov, zastajanje tekočine in slabost sta se pojavila pri približno 6 % bolnikov in driska pri 5 odstotkih bolnikov.
English: This contains a drying agent to keep the capsules dry.
Slovenian: V njem je sredstvo za sušenje, ki skrbi, da ostanejo kapsule suhe.
English: The platelet count will increase within 4 days of stopping treatment with anagrelide and will return to pre-treatment levels within 10 to 14 days, possibly rebounding above baseline values.
Slovenian: Število krvnih ploščic bo v štirih dneh po prenehanju zdravljenja z anagrelidom naraslo, po 10 do 14 dneh pa se bo vrnilo na raven pred zdravljenjem, lahko se zviša celo nad izhodiščne vrednosti.
English: Essential thrombocythaemia is a condition which occurs when the bone marrow produces too many of the blood cells known as platelets.
Slovenian: Esencialna trombocitemija je bolezen, do katere pride, ko kostni mozeg proizvaja preveliko število krvnih celic, ki jih poznamo kot krvne ploščice.
English: Following oral administration of anagrelide in man, at least 70% is absorbed from the gastrointestinal tract.
Slovenian: Po peroralni uporabi anagrelida pri človeku se iz prebavnega trakta vsrka vsaj 70 %.